Artificial Intelligence
Global Healthcare Distribution Market to Reach $3 Trillion by 2026
New York, Feb. 24, 2022 (GLOBE NEWSWIRE) — Reportlinker.com announces the release of the report “Global Healthcare Distribution Industry” – https://www.reportlinker.com/p06031757/?utm_source=GNW
-Online interactive peer-to-peer collaborative bespoke updates
-Access to our digital archives and MarketGlass Research Platform
-Complimentary updates for one year
Global Healthcare Distribution Market to Reach $3 Trillion by 2026
Distribution plays a key role as the distribution network is critical component of the supply chain that ensures the drugs reach the consumers. Proper distribution is a critical component that determines a drug`s commercial success. Drug distribution is a complex process and entails conformance to multiple regulations. In developed markets such as the US, the wholesale market is oligopolistic with a handful of large wholesalers, who sell to regional wholesalers and/or drugstore chains. On the other hand, drug distribution is a complex and fragmented business in most developing markets. The existence of a large number of small wholesalers and the absence of established retail chain networks makes it a complex process in such countries.
Amid the COVID-19 crisis, the global market for Healthcare Distribution estimated at US$876.2 Billion in the year 2020, is projected to reach a revised size of US$3 Trillion by 2026, growing at a CAGR of 20.2% over the analysis period. Pharmaceuticals, one of the segments analyzed in the report, is projected to grow at a 19.9% CAGR to reach US$1.3 Trillion by the end of the analysis period. After a thorough analysis of the business implications of the pandemic and its induced economic crisis, growth in the Biopharmaceuticals segment is readjusted to a revised 22.4% CAGR for the next 7-year period. This segment currently accounts for a 33.7% share of the global Healthcare Distribution market.
The U.S. Market is Estimated at $412.7 Billion in 2021, While China is Forecast to Reach $522.2 Billion by 2026
The Healthcare Distribution market in the U.S. is estimated at US$412.7 Billion in the year 2021. The country currently accounts for a 34.81% share in the global market. China, the world second largest economy, is forecast to reach an estimated market size of US$522.2 Billion in the year 2026 trailing a CAGR of 22.2% through the analysis period. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 18.1% and 18.5% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 20.5% CAGR while Rest of European market (as defined in the study) will reach US$561.3 Billion by the end of the analysis period. Retail pharmacies are a vital link in the drug supply chain as they form the main medium between the manufacturers, wholesalers, and pharmacy benefit managers on the supply side and the retail customers on the other side. Retail pharmacies are also the important cog in the wheel for processing claims of customers. Technology adoption is highly evolved in the US, and claim processing is mostly automated and handled electronically, leading to minimization of paper based manual processing, and maximization of efficiency.
Medical Devices Segment to Reach $612.3 Billion
In the global Medical Devices segment, USA, Canada, Japan, China and Europe will drive the 17.1% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$169.4 Billion in the year 2020 will reach a projected size of US$510.1 Billion by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$76.2 Billion by the year 2026, while Latin America will expand at a 17.4% CAGR through the analysis period.
Select Competitors (Total 61 Featured) –
- Accord-UK Ltd.
- ALLIANCE UNICHEM IP LIMITED
- AmerisourceBergen Corporation
- Attain Med, Inc.
- Cardinal Health, Inc.
- CuraScript SD
- Dakota Drug, Inc.
- Express Scripts Holding Company
- FedEx Corporation
- FFF Enterprises, Inc.
- Henry Schein Inc.
- KeySource Medical, Inc.
- McKesson Corporation
- Medline Industries
- Morris and Dickson Co., LLC
- Mutual Drug
- Owens & Minor, Inc.
- Patterson Companies Inc.
- PHOENIX Group
- Redington (India) Limited
- Shanghai Pharmaceutical Group Co., Ltd.
- Smith Drug Company
Read the full report: https://www.reportlinker.com/p06031757/?utm_source=GNW
I. METHODOLOGY
II. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
Influencer Market Insights
World Market Trajectories
Impact of Covid-19 and a Looming Global Recession
Healthcare Distribution – Global Key Competitors Percentage
Market Share in 2022 (E)
Competitive Market Presence – Strong/Active/Niche/Trivial for
Players Worldwide in 2022 (E)
The Race Between the Virus & Vaccines Intensifies. Amidst this
Chaotic Battle, Where is the World Economy Headed in 2021?
How Fast the World is Vaccinated Will Determine How Soon the
Pandemic Will End: Global Number of Annual COVID-19 Vaccine
Doses (In Million) for Years 2020 through 2025 by Geographic
Region/Country
Progress on Vaccinations, Why Should Businesses Care?
These are Times When Questions Abound & Answers Are Few
With IMF’s Upward Revision of Global GDP Forecasts for 2021,
Most Companies Are Bullish About a Global Economic Comeback.
A Strong 2021 Economic Rebound Based On Pent-Up Demand Comes as
a Relief for Suffering Industries & Markets: World Economic
Growth Projections (Real GDP, Annual % Change) for 2020
through 2022
Easing Unemployment Levels in 2021 Although Moderate Will
Infuse Hope for Industries Reliant on Consumer Discretionary
Incomes: Global Number of Unemployed People (In Million) for
Years 2017, 2019, 2020, and 2022
A Retrospective Review of Year 2020 as the Worst Year in
Humanity’s History that Left the World in Shambles &
Industries and Markets Upended
How the Healthcare Industry Has & Continues to be Impacted by
the Pandemic & What’s the New Normal?
The Biggest & Worst Ever Public Health Crisis in Human History
Creates a Mixed Bag of Challenges & Opportunities for the
Healthcare Industry
With the COVID-19 Pandemic Exposing Global Healthcare
Unpreparedness, There is Increasing Policy Led Focus on
Rebooting Health Systems Worldwide: Current & Required
Healthcare Spending as % of GDP
Clinical Diagnostic Laboratories Work Overtime to Manage Giant
Waves of COVID Infection Testing Flowing In
Global Clinical Diagnostics Market Reset & Trajectory – Growth
Outlook (In %) For Years 2019 Through 2025
The Pandemic Triggers Shift in Consumer Behavior & Engagement
With Healthcare Technologies & Services
Healthcare Industry Pushed to Adopt Digital Technologies &
Innovate to Save Lives Amid the Crisis
Digital Health Technologies Poised to Break New Grounds Post
Pandemic: Global Opportunity in Digital Health (In US$
Billion) for Years 2020, 2022, 2024 and 2026
How COVID-19 Outbreak Sent the Healthcare Supply Chain Into a
Tailspin
Unprecedented Losses Sustained in the Supply Chain Bodes Well
for Integration of Emerging Technologies like Blockchain to
Enhance Resilience & Reliability: Global Losses in Supply
Chain as a % of Earnings Before Interest, Taxes,
Depreciation & Amortization (EBITDA) in the Year 2020
Far-Flung Supply Chains of the Pharma Industry Cannot be
Consolidated Easily & Abruptly, But the Winds of Change Blown
by COVID-19 Can Be Felt: Global Number of Plants Registered
with the U.S. to Supply Active Pharmaceutical Ingredients as
of the Year 2020
Healthcare Supply Chain Management Storms Into the Spotlight to
Address Disruptions Posed by the Crisis
With Smart Management of Supply Chains Being the Need of the
Hour, Healthcare Supply Chain Management to Reach New Highs:
Global Opportunity in Healthcare Supply Chain Management (In
US$ Million) for Years 2020, 2022, 2024, 2026
Recent Market Activity
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
Substandard Drugs, an Urgent Challenge in the Supply Chain that
Begs to be Addressed
Pharmaceutical Thefts & Counterfeiting, A Persistent Challenge
in Distribution That Eludes Resolution
Online Pharmacies Growth Leads to Global Presence of
Counterfeit Drugs
Storming Into the Spotlight Is the Use of Blockchain in
Fighting Counterfeiting of Drugs
Rising Incidence of Counterfeiting in the Pharmaceutical
Industry Pushes Up the Urgency to Leverage the Security
Benefits Promised by Blockchain: Global Number of
Pharmaceutical Counterfeiting Incidents for Years 2000,
2005, 2010, 2015, 2019 & 2022
Serialization Emerges as an Another Weapon in the Arsenal to
Battle Counterfeiting
Rising Healthcare Costs Drives Attractiveness of e-Pharmacies
Here’s How Healthcare Costs Are Outstripping Global GDP:
Healthcare Costs as a % of GDP by Country for the Years 2020 &
2023
Social Distancing Amid the COVID-19 Pandemic Accelerates the
Viability & Indispensability of e-Pharmacies, Fast Forwarding
Growth by Over 2 Years
Global ePharmacy Sales Breakdown (In %) by OTC Drugs & RX Drugs
As of the Year 2021
Aging Population, Rising Prevalence of Chronic Diseases &
Ensuing Demand for Drugs & Medical Equipment Rank as Major
Drivers of Growth in the Market
Aging Population Steps-Up the Burden On Healthcare Systems
Including Distribution: Global Aging Population Statistics for
the 65+ Age Group in Million by Geographic Region for the
Years 2019, 2025, 2035 and 2050
Rising Prevalence of Chronic Diseases Amplifies Demand for
Pharmaceutical Drugs & Distribution: Global Cost of Chronic
Diseases (In US$ Billion) for the Years 2018 and 2030
Robust Demand for Pharmaceutical Drugs Drives Growth in the Market
Pharmaceutical Contract Manufacturing, a Barometer of the
Growing Demand & Production of Drugs
More Drugs Being Manufactured Means More Drugs in Distribution:
Global Opportunity for Pharmaceutical Contract Manufacturing
(In US$ Billion) for Years 2020, 2022, 2024, and 2026
Artificial Intelligence to Revolutionize Pharmaceutical Retailing
As the World Ramps Up Production of COVID-19 Vaccines,
Distribution Emerges Into the Spotlight
As Mass Vaccination Drives Kick-in Challenges in Covid-19
Vaccine Distribution Begin to Surface
A Review of Vaccine Distribution Approach in the US
4. GLOBAL MARKET PERSPECTIVE
Table 1: World Recent Past, Current & Future Analysis for
Healthcare Distribution by Geographic Region – USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Middle East
and Africa Markets – Independent Analysis of Annual Revenues in
US$ Million for Years 2020 through 2027 and % CAGR
Table 2: World Historic Review for Healthcare Distribution by
Geographic Region – USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets –
Independent Analysis of Annual Revenues in US$ Million for
Years 2012 through 2019 and % CAGR
Table 3: World 15-Year Perspective for Healthcare Distribution
by Geographic Region – Percentage Breakdown of Value Revenues
for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets for Years 2012, 2021 &
2027
Table 4: World Recent Past, Current & Future Analysis for
Pharmaceutical by Geographic Region – USA, Canada, Japan,
China, Europe, Asia-Pacific, Latin America, Middle East and
Africa Markets – Independent Analysis of Annual Revenues in US$
Million for Years 2020 through 2027 and % CAGR
Table 5: World Historic Review for Pharmaceutical by Geographic
Region – USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets – Independent Analysis
of Annual Revenues in US$ Million for Years 2012 through 2019
and % CAGR
Table 6: World 15-Year Perspective for Pharmaceutical by
Geographic Region – Percentage Breakdown of Value Revenues for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2021 & 2027
Table 7: World Recent Past, Current & Future Analysis for
Biopharmaceutical by Geographic Region – USA, Canada, Japan,
China, Europe, Asia-Pacific, Latin America, Middle East and
Africa Markets – Independent Analysis of Annual Revenues in US$
Million for Years 2020 through 2027 and % CAGR
Table 8: World Historic Review for Biopharmaceutical by
Geographic Region – USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets –
Independent Analysis of Annual Revenues in US$ Million for
Years 2012 through 2019 and % CAGR
Table 9: World 15-Year Perspective for Biopharmaceutical by
Geographic Region – Percentage Breakdown of Value Revenues for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2021 & 2027
Table 10: World Recent Past, Current & Future Analysis for
Medical Devices by Geographic Region – USA, Canada, Japan,
China, Europe, Asia-Pacific, Latin America, Middle East and
Africa Markets – Independent Analysis of Annual Revenues in US$
Million for Years 2020 through 2027 and % CAGR
Table 11: World Historic Review for Medical Devices by
Geographic Region – USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets –
Independent Analysis of Annual Revenues in US$ Million for
Years 2012 through 2019 and % CAGR
Table 12: World 15-Year Perspective for Medical Devices by
Geographic Region – Percentage Breakdown of Value Revenues for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2021 & 2027
Table 13: World Recent Past, Current & Future Analysis for
Retail Pharmacies by Geographic Region – USA, Canada, Japan,
China, Europe, Asia-Pacific, Latin America, Middle East and
Africa Markets – Independent Analysis of Annual Revenues in US$
Million for Years 2020 through 2027 and % CAGR
Table 14: World Historic Review for Retail Pharmacies by
Geographic Region – USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets –
Independent Analysis of Annual Revenues in US$ Million for
Years 2012 through 2019 and % CAGR
Table 15: World 15-Year Perspective for Retail Pharmacies by
Geographic Region – Percentage Breakdown of Value Revenues for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2021 & 2027
Table 16: World Recent Past, Current & Future Analysis for
Hospital Pharmacies by Geographic Region – USA, Canada, Japan,
China, Europe, Asia-Pacific, Latin America, Middle East and
Africa Markets – Independent Analysis of Annual Revenues in US$
Million for Years 2020 through 2027 and % CAGR
Table 17: World Historic Review for Hospital Pharmacies by
Geographic Region – USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets –
Independent Analysis of Annual Revenues in US$ Million for
Years 2012 through 2019 and % CAGR
Table 18: World 15-Year Perspective for Hospital Pharmacies by
Geographic Region – Percentage Breakdown of Value Revenues for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2021 & 2027
Table 19: World Recent Past, Current & Future Analysis for
Other End Uses by Geographic Region – USA, Canada, Japan,
China, Europe, Asia-Pacific, Latin America, Middle East and
Africa Markets – Independent Analysis of Annual Revenues in US$
Million for Years 2020 through 2027 and % CAGR
Table 20: World Historic Review for Other End Uses by
Geographic Region – USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets –
Independent Analysis of Annual Revenues in US$ Million for
Years 2012 through 2019 and % CAGR
Table 21: World 15-Year Perspective for Other End Uses by
Geographic Region – Percentage Breakdown of Value Revenues for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2021 & 2027
III. MARKET ANALYSIS
UNITED STATES
Healthcare Distribution Market Presence – Strong/Active/Niche/
Trivial – Key Competitors in the United States for 2022 (E)
Table 22: USA Recent Past, Current & Future Analysis for
Healthcare Distribution by Product Type – Pharmaceutical,
Biopharmaceutical and Medical Devices – Independent Analysis of
Annual Revenues in US$ Million for the Years 2020 through 2027
and % CAGR
Table 23: USA Historic Review for Healthcare Distribution by
Product Type – Pharmaceutical, Biopharmaceutical and Medical
Devices Markets – Independent Analysis of Annual Revenues in
US$ Million for Years 2012 through 2019 and % CAGR
Table 24: USA 15-Year Perspective for Healthcare Distribution
by Product Type – Percentage Breakdown of Value Revenues for
Pharmaceutical, Biopharmaceutical and Medical Devices for the
Years 2012, 2021 & 2027
Table 25: USA Recent Past, Current & Future Analysis for
Healthcare Distribution by End-Use – Retail Pharmacies,
Hospital Pharmacies and Other End Uses – Independent Analysis
of Annual Revenues in US$ Million for the Years 2020 through
2027 and % CAGR
Table 26: USA Historic Review for Healthcare Distribution by
End-Use – Retail Pharmacies, Hospital Pharmacies and Other End
Uses Markets – Independent Analysis of Annual Revenues in US$
Million for Years 2012 through 2019 and % CAGR
Table 27: USA 15-Year Perspective for Healthcare Distribution
by End-Use – Percentage Breakdown of Value Revenues for Retail
Pharmacies, Hospital Pharmacies and Other End Uses for the
Years 2012, 2021 & 2027
CANADA
Table 28: Canada Recent Past, Current & Future Analysis for
Healthcare Distribution by Product Type – Pharmaceutical,
Biopharmaceutical and Medical Devices – Independent Analysis of
Annual Revenues in US$ Million for the Years 2020 through 2027
and % CAGR
Table 29: Canada Historic Review for Healthcare Distribution by
Product Type – Pharmaceutical, Biopharmaceutical and Medical
Devices Markets – Independent Analysis of Annual Revenues in
US$ Million for Years 2012 through 2019 and % CAGR
Table 30: Canada 15-Year Perspective for Healthcare
Distribution by Product Type – Percentage Breakdown of Value
Revenues for Pharmaceutical, Biopharmaceutical and Medical
Devices for the Years 2012, 2021 & 2027
Table 31: Canada Recent Past, Current & Future Analysis for
Healthcare Distribution by End-Use – Retail Pharmacies,
Hospital Pharmacies and Other End Uses – Independent Analysis
of Annual Revenues in US$ Million for the Years 2020 through
2027 and % CAGR
Table 32: Canada Historic Review for Healthcare Distribution by
End-Use – Retail Pharmacies, Hospital Pharmacies and Other End
Uses Markets – Independent Analysis of Annual Revenues in US$
Million for Years 2012 through 2019 and % CAGR
Table 33: Canada 15-Year Perspective for Healthcare
Distribution by End-Use – Percentage Breakdown of Value
Revenues for Retail Pharmacies, Hospital Pharmacies and Other
End Uses for the Years 2012, 2021 & 2027
JAPAN
Healthcare Distribution Market Presence – Strong/Active/Niche/
Trivial – Key Competitors in Japan for 2022 (E)
Table 34: Japan Recent Past, Current & Future Analysis for
Healthcare Distribution by Product Type – Pharmaceutical,
Biopharmaceutical and Medical Devices – Independent Analysis of
Annual Revenues in US$ Million for the Years 2020 through 2027
and % CAGR
Table 35: Japan Historic Review for Healthcare Distribution by
Product Type – Pharmaceutical, Biopharmaceutical and Medical
Devices Markets – Independent Analysis of Annual Revenues in
US$ Million for Years 2012 through 2019 and % CAGR
Table 36: Japan 15-Year Perspective for Healthcare Distribution
by Product Type – Percentage Breakdown of Value Revenues for
Pharmaceutical, Biopharmaceutical and Medical Devices for the
Years 2012, 2021 & 2027
Table 37: Japan Recent Past, Current & Future Analysis for
Healthcare Distribution by End-Use – Retail Pharmacies,
Hospital Pharmacies and Other End Uses – Independent Analysis
of Annual Revenues in US$ Million for the Years 2020 through
2027 and % CAGR
Table 38: Japan Historic Review for Healthcare Distribution by
End-Use – Retail Pharmacies, Hospital Pharmacies and Other End
Uses Markets – Independent Analysis of Annual Revenues in US$
Million for Years 2012 through 2019 and % CAGR
Table 39: Japan 15-Year Perspective for Healthcare Distribution
by End-Use – Percentage Breakdown of Value Revenues for Retail
Pharmacies, Hospital Pharmacies and Other End Uses for the
Years 2012, 2021 & 2027
CHINA
Healthcare Distribution Market Presence – Strong/Active/Niche/
Trivial – Key Competitors in China for 2022 (E)
Table 40: China Recent Past, Current & Future Analysis for
Healthcare Distribution by Product Type – Pharmaceutical,
Biopharmaceutical and Medical Devices – Independent Analysis of
Annual Revenues in US$ Million for the Years 2020 through 2027
and % CAGR
Table 41: China Historic Review for Healthcare Distribution by
Product Type – Pharmaceutical, Biopharmaceutical and Medical
Devices Markets – Independent Analysis of Annual Revenues in
US$ Million for Years 2012 through 2019 and % CAGR
Table 42: China 15-Year Perspective for Healthcare Distribution
by Product Type – Percentage Breakdown of Value Revenues for
Pharmaceutical, Biopharmaceutical and Medical Devices for the
Years 2012, 2021 & 2027
Table 43: China Recent Past, Current & Future Analysis for
Healthcare Distribution by End-Use – Retail Pharmacies,
Hospital Pharmacies and Other End Uses – Independent Analysis
of Annual Revenues in US$ Million for the Years 2020 through
2027 and % CAGR
Table 44: China Historic Review for Healthcare Distribution by
End-Use – Retail Pharmacies, Hospital Pharmacies and Other End
Uses Markets – Independent Analysis of Annual Revenues in US$
Million for Years 2012 through 2019 and % CAGR
Table 45: China 15-Year Perspective for Healthcare Distribution
by End-Use – Percentage Breakdown of Value Revenues for Retail
Pharmacies, Hospital Pharmacies and Other End Uses for the
Years 2012, 2021 & 2027
EUROPE
Healthcare Distribution Market Presence – Strong/Active/Niche/
Trivial – Key Competitors in Europe for 2022 (E)
Table 46: Europe Recent Past, Current & Future Analysis for
Healthcare Distribution by Geographic Region – France, Germany,
Italy, UK, Spain, Russia and Rest of Europe Markets –
Independent Analysis of Annual Revenues in US$ Million for
Years 2020 through 2027 and % CAGR
Table 47: Europe Historic Review for Healthcare Distribution by
Geographic Region – France, Germany, Italy, UK, Spain, Russia
and Rest of Europe Markets – Independent Analysis of Annual
Revenues in US$ Million for Years 2012 through 2019 and % CAGR
Table 48: Europe 15-Year Perspective for Healthcare
Distribution by Geographic Region – Percentage Breakdown of
Value Revenues for France, Germany, Italy, UK, Spain, Russia
and Rest of Europe Markets for Years 2012, 2021 & 2027
Table 49: Europe Recent Past, Current & Future Analysis for
Healthcare Distribution by Product Type – Pharmaceutical,
Biopharmaceutical and Medical Devices – Independent Analysis of
Annual Revenues in US$ Million for the Years 2020 through 2027
and % CAGR
Table 50: Europe Historic Review for Healthcare Distribution by
Product Type – Pharmaceutical, Biopharmaceutical and Medical
Devices Markets – Independent Analysis of Annual Revenues in
US$ Million for Years 2012 through 2019 and % CAGR
Table 51: Europe 15-Year Perspective for Healthcare
Distribution by Product Type – Percentage Breakdown of Value
Revenues for Pharmaceutical, Biopharmaceutical and Medical
Devices for the Years 2012, 2021 & 2027
Table 52: Europe Recent Past, Current & Future Analysis for
Healthcare Distribution by End-Use – Retail Pharmacies,
Hospital Pharmacies and Other End Uses – Independent Analysis
of Annual Revenues in US$ Million for the Years 2020 through
2027 and % CAGR
Table 53: Europe Historic Review for Healthcare Distribution by
End-Use – Retail Pharmacies, Hospital Pharmacies and Other End
Uses Markets – Independent Analysis of Annual Revenues in US$
Million for Years 2012 through 2019 and % CAGR
Table 54: Europe 15-Year Perspective for Healthcare
Distribution by End-Use – Percentage Breakdown of Value
Revenues for Retail Pharmacies, Hospital Pharmacies and Other
End Uses for the Years 2012, 2021 & 2027
FRANCE
Healthcare Distribution Market Presence – Strong/Active/Niche/
Trivial – Key Competitors in France for 2022 (E)
Table 55: France Recent Past, Current & Future Analysis for
Healthcare Distribution by Product Type – Pharmaceutical,
Biopharmaceutical and Medical Devices – Independent Analysis of
Annual Revenues in US$ Million for the Years 2020 through 2027
and % CAGR
Table 56: France Historic Review for Healthcare Distribution by
Product Type – Pharmaceutical, Biopharmaceutical and Medical
Devices Markets – Independent Analysis of Annual Revenues in
US$ Million for Years 2012 through 2019 and % CAGR
Table 57: France 15-Year Perspective for Healthcare
Distribution by Product Type – Percentage Breakdown of Value
Revenues for Pharmaceutical, Biopharmaceutical and Medical
Devices for the Years 2012, 2021 & 2027
Table 58: France Recent Past, Current & Future Analysis for
Healthcare Distribution by End-Use – Retail Pharmacies,
Hospital Pharmacies and Other End Uses – Independent Analysis
of Annual Revenues in US$ Million for the Years 2020 through
2027 and % CAGR
Table 59: France Historic Review for Healthcare Distribution by
End-Use – Retail Pharmacies, Hospital Pharmacies and Other End
Uses Markets – Independent Analysis of Annual Revenues in US$
Million for Years 2012 through 2019 and % CAGR
Table 60: France 15-Year Perspective for Healthcare
Distribution by End-Use – Percentage Breakdown of Value
Revenues for Retail Pharmacies, Hospital Pharmacies and Other
End Uses for the Years 2012, 2021 & 2027
GERMANY
Healthcare Distribution Market Presence – Strong/Active/Niche/
Trivial – Key Competitors in Germany for 2022 (E)
Table 61: Germany Recent Past, Current & Future Analysis for
Healthcare Distribution by Product Type – Pharmaceutical,
Biopharmaceutical and Medical Devices – Independent Analysis of
Annual Revenues in US$ Million for the Years 2020 through 2027
and % CAGR
Table 62: Germany Historic Review for Healthcare Distribution
by Product Type – Pharmaceutical, Biopharmaceutical and Medical
Devices Markets – Independent Analysis of Annual Revenues in
US$ Million for Years 2012 through 2019 and % CAGR
Table 63: Germany 15-Year Perspective for Healthcare
Distribution by Product Type – Percentage Breakdown of Value
Revenues for Pharmaceutical, Biopharmaceutical and Medical
Devices for the Years 2012, 2021 & 2027
Table 64: Germany Recent Past, Current & Future Analysis for
Healthcare Distribution by End-Use – Retail Pharmacies,
Hospital Pharmacies and Other End Uses – Independent Analysis
of Annual Revenues in US$ Million for the Years 2020 through
2027 and % CAGR
Table 65: Germany Historic Review for Healthcare Distribution
by End-Use – Retail Pharmacies, Hospital Pharmacies and Other
End Uses Markets – Independent Analysis of Annual Revenues in
US$ Million for Years 2012 through 2019 and % CAGR
Table 66: Germany 15-Year Perspective for Healthcare
Distribution by End-Use – Percentage Breakdown of Value
Revenues for Retail Pharmacies, Hospital Pharmacies and Other
End Uses for the Years 2012, 2021 & 2027
ITALY
Table 67: Italy Recent Past, Current & Future Analysis for
Healthcare Distribution by Product Type – Pharmaceutical,
Biopharmaceutical and Medical Devices – Independent Analysis of
Annual Revenues in US$ Million for the Years 2020 through 2027
and % CAGR
Table 68: Italy Historic Review for Healthcare Distribution by
Product Type – Pharmaceutical, Biopharmaceutical and Medical
Devices Markets – Independent Analysis of Annual Revenues in
US$ Million for Years 2012 through 2019 and % CAGR
Table 69: Italy 15-Year Perspective for Healthcare Distribution
by Product Type – Percentage Breakdown of Value Revenues for
Pharmaceutical, Biopharmaceutical and Medical Devices for the
Years 2012, 2021 & 2027
Table 70: Italy Recent Past, Current & Future Analysis for
Healthcare Distribution by End-Use – Retail Pharmacies,
Hospital Pharmacies and Other End Uses – Independent Analysis
of Annual Revenues in US$ Million for the Years 2020 through
2027 and % CAGR
Table 71: Italy Historic Review for Healthcare Distribution by
End-Use – Retail Pharmacies, Hospital Pharmacies and Other End
Uses Markets – Independent Analysis of Annual Revenues in US$
Million for Years 2012 through 2019 and % CAGR
Table 72: Italy 15-Year Perspective for Healthcare Distribution
by End-Use – Percentage Breakdown of Value Revenues for Retail
Pharmacies, Hospital Pharmacies and Other End Uses for the
Years 2012, 2021 & 2027
UNITED KINGDOM
Healthcare Distribution Market Presence – Strong/Active/Niche/
Trivial – Key Competitors in the United Kingdom for 2022 (E)
Table 73: UK Recent Past, Current & Future Analysis for
Healthcare Distribution by Product Type – Pharmaceutical,
Biopharmaceutical and Medical Devices – Independent Analysis of
Annual Revenues in US$ Million for the Years 2020 through 2027
and % CAGR
Table 74: UK Historic Review for Healthcare Distribution by
Product Type – Pharmaceutical, Biopharmaceutical and Medical
Devices Markets – Independent Analysis of Annual Revenues in
US$ Million for Years 2012 through 2019 and % CAGR
Table 75: UK 15-Year Perspective for Healthcare Distribution by
Product Type – Percentage Breakdown of Value Revenues for
Pharmaceutical, Biopharmaceutical and Medical Devices for the
Years 2012, 2021 & 2027
Table 76: UK Recent Past, Current & Future Analysis for
Healthcare Distribution by End-Use – Retail Pharmacies,
Hospital Pharmacies and Other End Uses – Independent Analysis
of Annual Revenues in US$ Million for the Years 2020 through
2027 and % CAGR
Table 77: UK Historic Review for Healthcare Distribution by
End-Use – Retail Pharmacies, Hospital Pharmacies and Other End
Uses Markets – Independent Analysis of Annual Revenues in US$
Million for Years 2012 through 2019 and % CAGR
Table 78: UK 15-Year Perspective for Healthcare Distribution by
End-Use – Percentage Breakdown of Value Revenues for Retail
Pharmacies, Hospital Pharmacies and Other End Uses for the
Years 2012, 2021 & 2027
SPAIN
Table 79: Spain Recent Past, Current & Future Analysis for
Healthcare Distribution by Product Type – Pharmaceutical,
Biopharmaceutical and Medical Devices – Independent Analysis of
Annual Revenues in US$ Million for the Years 2020 through 2027
and % CAGR
Table 80: Spain Historic Review for Healthcare Distribution by
Product Type – Pharmaceutical, Biopharmaceutical and Medical
Devices Markets – Independent Analysis of Annual Revenues in
US$ Million for Years 2012 through 2019 and % CAGR
Table 81: Spain 15-Year Perspective for Healthcare Distribution
by Product Type – Percentage Breakdown of Value Revenues for
Pharmaceutical, Biopharmaceutical and Medical Devices for the
Years 2012, 2021 & 2027
Table 82: Spain Recent Past, Current & Future Analysis for
Healthcare Distribution by End-Use – Retail Pharmacies,
Hospital Pharmacies and Other End Uses – Independent Analysis
of Annual Revenues in US$ Million for the Years 2020 through
2027 and % CAGR
Table 83: Spain Historic Review for Healthcare Distribution by
End-Use – Retail Pharmacies, Hospital Pharmacies and Other End
Uses Markets – Independent Analysis of Annual Revenues in US$
Million for Years 2012 through 2019 and % CAGR
Table 84: Spain 15-Year Perspective for Healthcare Distribution
by End-Use – Percentage Breakdown of Value Revenues for Retail
Pharmacies, Hospital Pharmacies and Other End Uses for the
Years 2012, 2021 & 2027
RUSSIA
Table 85: Russia Recent Past, Current & Future Analysis for
Healthcare Distribution by Product Type – Pharmaceutical,
Biopharmaceutical and Medical Devices – Independent Analysis of
Annual Revenues in US$ Million for the Years 2020 through 2027
and % CAGR
Table 86: Russia Historic Review for Healthcare Distribution by
Product Type – Pharmaceutical, Biopharmaceutical and Medical
Devices Markets – Independent Analysis of Annual Revenues in
US$ Million for Years 2012 through 2019 and % CAGR
Table 87: Russia 15-Year Perspective for Healthcare
Distribution by Product Type – Percentage Breakdown of Value
Revenues for Pharmaceutical, Biopharmaceutical and Medical
Devices for the Years 2012, 2021 & 2027
Table 88: Russia Recent Past, Current & Future Analysis for
Healthcare Distribution by End-Use – Retail Pharmacies,
Hospital Pharmacies and Other End Uses – Independent Analysis
of Annual Revenues in US$ Million for the Years 2020 through
2027 and % CAGR
Table 89: Russia Historic Review for Healthcare Distribution by
End-Use – Retail Pharmacies, Hospital Pharmacies and Other End
Uses Markets – Independent Analysis of Annual Revenues in US$
Million for Years 2012 through 2019 and % CAGR
Table 90: Russia 15-Year Perspective for Healthcare
Distribution by End-Use – Percentage Breakdown of Value
Revenues for Retail Pharmacies, Hospital Pharmacies and Other
End Uses for the Years 2012, 2021 & 2027
REST OF EUROPE
Table 91: Rest of Europe Recent Past, Current & Future Analysis
for Healthcare Distribution by Product Type – Pharmaceutical,
Biopharmaceutical and Medical Devices – Independent Analysis of
Annual Revenues in US$ Million for the Years 2020 through 2027
and % CAGR
Table 92: Rest of Europe Historic Review for Healthcare
Distribution by Product Type – Pharmaceutical,
Biopharmaceutical and Medical Devices Markets – Independent
Analysis of Annual Revenues in US$ Million for Years 2012
through 2019 and % CAGR
Table 93: Rest of Europe 15-Year Perspective for Healthcare
Distribution by Product Type – Percentage Breakdown of Value
Revenues for Pharmaceutical, Biopharmaceutical and Medical
Devices for the Years 2012, 2021 & 2027
Table 94: Rest of Europe Recent Past, Current & Future Analysis
for Healthcare Distribution by End-Use – Retail Pharmacies,
Hospital Pharmacies and Other End Uses – Independent Analysis
of Annual Revenues in US$ Million for the Years 2020 through
2027 and % CAGR
Table 95: Rest of Europe Historic Review for Healthcare
Distribution by End-Use – Retail Pharmacies, Hospital
Pharmacies and Other End Uses Markets – Independent Analysis of
Annual Revenues in US$ Million for Years 2012 through 2019 and
% CAGR
Table 96: Rest of Europe 15-Year Perspective for Healthcare
Distribution by End-Use – Percentage Breakdown of Value
Revenues for Retail Pharmacies, Hospital Pharmacies and Other
End Uses for the Years 2012, 2021 & 2027
ASIA-PACIFIC
Healthcare Distribution Market Presence – Strong/Active/Niche/
Trivial – Key Competitors in Asia-Pacific for 2022 (E)
Table 97: Asia-Pacific Recent Past, Current & Future Analysis
for Healthcare Distribution by Geographic Region – Australia,
India, South Korea and Rest of Asia-Pacific Markets –
Independent Analysis of Annual Revenues in US$ Million for
Years 2020 through 2027 and % CAGR
Table 98: Asia-Pacific Historic Review for Healthcare
Distribution by Geographic Region – Australia, India, South
Korea and Rest of Asia-Pacific Markets – Independent Analysis
of Annual Revenues in US$ Million for Years 2012 through 2019
and % CAGR
Table 99: Asia-Pacific 15-Year Perspective for Healthcare
Distribution by Geographic Region – Percentage Breakdown of
Value Revenues for Australia, India, South Korea and Rest of
Asia-Pacific Markets for Years 2012, 2021 & 2027
Table 100: Asia-Pacific Recent Past, Current & Future Analysis
for Healthcare Distribution by Product Type – Pharmaceutical,
Biopharmaceutical and Medical Devices – Independent Analysis of
Annual Revenues in US$ Million for the Years 2020 through 2027
and % CAGR
Table 101: Asia-Pacific Historic Review for Healthcare
Distribution by Product Type – Pharmaceutical,
Biopharmaceutical and Medical Devices Markets – Independent
Analysis of Annual Revenues in US$ Million for Years 2012
through 2019 and % CAGR
Table 102: Asia-Pacific 15-Year Perspective for Healthcare
Distribution by Product Type – Percentage Breakdown of Value
Revenues for Pharmaceutical, Biopharmaceutical and Medical
Devices for the Years 2012, 2021 & 2027
Please contact our Customer Support Center to get the complete Table of Contents
Read the full report: https://www.reportlinker.com/p06031757/?utm_source=GNW
About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need – instantly, in one place.
__________________________
Artificial Intelligence
ICIS announces the 16th Asian Base Oils and Lubricants Conference in Singapore
LONDON, May 20, 2024 /PRNewswire/ — ICIS, a global source of commodity intelligence, has announced the 16th Asian Base Oils and Lubricants Conference will take place in Singapore, 27-28 June 2024. The event offers a platform for senior executives to connect with peers, potential clients and industry leaders, offering insight into the latest trends, innovation and best practices within the industry.
Dr Sarawut Kaewtathip, Director General – Department of Mineral Fuels from the Ministry of Energy, Thailand will present a keynote delving into the Thai fuels and lubricants market. He will offer insight into growth opportunities within the automotive sector following COVID-19 and explain how the base oils and lubricants industry can support future developments.
The conference will also include exclusive market data from Michael Connolly, Principal Analyst, Refining at ICIS, who comments: “While Asian prices have been less impacted by global events than in other regions, it has still been affected, which is highlighted by further Group I closures in the region. This conference provides a vital platform to exchange knowledge and come together to learn collectively about the latest industry developments, whilst finding out how to best navigate uncertainty in the coming years.”
Delegates will also benefit from insight by Yan Chuang Zhao, Supervising Engineer of R&D Center at Great Wall Motors, who will be discussing ‘The wider Electric Vehicle picture in Asia’ and Charlotte Kehoe, AsPac Technology Director at bp Castrol who, who adds to the extensive line-up of speakers that conference attendees have come accustomed to. Charlotte will be looking to provide further insight into opportunities with data centres and immersion coolants across the region.
To find out more about the 16th ICIS Asian Base Oils and Lubricants Conference, or register for the event, please visit: https://events.icis.com/asian-base-oils/
About ICIS
ICIS – Independent Commodity Intelligence Services – helps businesses through seamlessly delivering data and analytics, across the chemical, and energy markets. A trusted source and benchmark for price information and insight across key commodities markets worldwide. Our independent, transparent market intelligence informs thousands of quality decisions every day, taking the pressure out of negotiations and giving customers space for more innovative thinking, through published datasets including price assessments, price forecasts, supply and demand fundamentals and more.
Over 150 years of shaping the world by connecting markets to optimise the world’s valuable resources. With a global team of more than 600 experts, ICIS has employees based in London, New York, Houston, Karlsruhe, Milan, Mumbai, Singapore, Guangzhou, Beijing, Shanghai, Dubai, Sao Paulo, Seoul, Tokyo and Perth.
ICIS is part of RELX, a FTSE15 company with a market cap of $78.2bn and an employee base of over 30,000 experts across 40 countries.
About RELX
RELX is a global provider of information and analytics for professional and business customers across industries. The Group serves customers in more than 180 countries and has offices in about 40 countries. It employs approximately 30,000 people of whom almost half are in North America. RELX PLC is a London listed holding company which owns 52.9% of RELX Group. RELX NV is an Amsterdam listed holding company which owns 47.1% of RELX Group. The shares are traded on the London, Amsterdam and New York Stock Exchanges using the following ticker symbols: London: REL; Amsterdam: REN; New York: RELX and RENX. Total market capitalisation is approximately £64.7bn | €75.5bn | $81.9bn.
Logo – https://mma.prnewswire.com/media/619935/4713254/ICIS_Logo.jpg
View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/icis-announces-the-16th-asian-base-oils-and-lubricants-conference-in-singapore-302149492.html
Artificial Intelligence
Subang Jaya Medical Centre Applauded by Frost & Sullivan as the Best Hospital Company of the Year in Malaysia for the fourth consecutive year
SJMC’s significant efforts in alleviating nursing shortages, enhancing workflows and its strong market-leading position, both locally and globally resulted in high patient retention and strong referrals.
SAN ANTONIO, May 20, 2024 /PRNewswire/ — Frost & Sullivan recently analyzed the hospital industry and noted that operational inefficiencies, workflow interruptions and shortage of skilled healthcare professionals are some key challenges faced by the healthcare industry. Based on its findings, Subang Jaya Medical Centre (SJMC) is recognized with the 2024 Malaysian Best Hospital Company of the Year Award for the fourth consecutive year in the hospitals industry, making it the first to be recognized continuously with this prestigious accolades
The company is a private hospital with 443 licensed beds and over 150 outpatient clinics. It handles approximately 50,000 admissions and 550,000 outpatient visits annually. With a workforce of around 1,600 healthcare professionals, SJMC offers services across more than 260 medical specialties encompassing diverse therapeutic areas such as oncology, cardiology, orthopedics, digestive health as well as women and children health.
Bhaskar Vittal, industry principal at Frost & Sullivan, observed, “SJMC provides comprehensive and integrated care, implementing practices aimed at achieving the best possible outcomes for patients. A typical cancer patient journey at SJMC starts with awareness-building and screening programs, continuing with diagnosis, treatment, and aftercare, which includes support groups, educators, and counselors—all key elements in cancer care management.
SJMC is a finalist flagship medical tourism hospital selected by the Malaysian Healthcare Travel Council (MHTC) which is fully endorsed by the Malaysian Ministry of Health. It has achieved several accreditations including the Joint Commission International (JCI) Accreditation and aims at providing patients a seamless transition throughout their health journey in Malaysia. Patient onboarding follows a process-oriented approach from the inquiry level, where patients receive detailed information on available services, specialist doctors, and treatment availability.
SJMC has achieved international branding and recognition for its Cancer & Radiosurgery Centre (CRC), known for its person-centered care approach. Moreover, the hospital has been credited by the Australian Council on Healthcare Standards International (ACHSI) as the first Center of Excellence (CoE) for oncology services in Asia-Pacific, marking a milestone achievement. SJMC continuously improves patient treatment options, expands day care surgical offerings, and prioritizes safety, faster recovery, and lower costs in line with industry trends to achieve medical excellence.
The hospital’s Genetic Wellness, a first-of-its-kind clinical-grade genetics testing program, provides more than 1,000 insights into patients’ health conditions based on their unique genetic blueprint. The test provides individualized information on a wide range of conditions, including chronic, infectious, and metabolic diseases, allergies, and drug responses, allowing individuals to make informed choices for their overall wellbeing.
SJMC became the first hospital in Malaysia to introduce a remote patient monitoring system, SeniorConnect, that is tailored to the unique needs of senior patients and is particularly beneficial in urban settings, where it is common for working adults to face challenges in caring for their elderly relatives. It is also the first hospital in Malaysia to perform day care robotic-assisted total knee replacement and total hip replacement procedures using the Mako SmartRobotics system. It also focuses on preventive and precision healthcare—key trends in the global healthcare industry.
Its continuous glucose monitoring (CGM) technology allows diabetes patients to continuously monitor and control their blood glucose. SJMC also successfully conducted a clinical improvement project, titled “Reducing Early Morning In-Patient Hypoglycemia Incidence among In-Patient Adults with Type 2 Diabetes Mellitus in non-Critical Care Wards,” which found that patients adhering to the recommended snack regimen experienced zero hypoglycemic incidents. SJMC aims to enhance diabetes wellness with its multidisciplinary approach through revolutionary technology and in-depth research.
SJMC’s artificial intelligence (AI)-powered Radixact X9 with Synchrony synchronizes the movement of radiation beams with the tumor’s motion, allowing seamless and continuous radiation delivery during the patient’s natural breathing patterns. This technology enables delivering accurate radiation dosage while minimizing exposure to healthy tissues.
“SJMC’s digital technologies and equipment enhance the patient journey, improve clinical outcomes, and provide the healthcare workforce with the best tools to achieve their medical excellence goals,” added Vittal.
Bryan Lin, Chief Executive Officer of SJMC expressed his gratitude for receiving this prestigious recognition for the fourth time, saying, “We’re honored to be recognized for the exceptional care our dedicated staff provides. Their unwavering commitment and teamwork are what truly make a difference for our patients. We’ll continue to pursue excellence and deliver world-class healthcare.”
“In today’s healthcare landscape, strengthening the healthcare workforce, enhancing workflows, and solidifying our market-leading position are paramount. We’re committed to achieving these goals by empowering our staff through training which improves the quality of patient care and equipping them with tools that enhance decision-making while encouraging them to embrace and learn in this digital healthcare era,” he adds.
With its excellent financial performance, seamless customer experiences, and strong overall performance, Subang Jaya Medical Centre’s unwavering dedication to exceptional healthcare is again recognized on the international stage, with their fourth consecutive award win.
Each year, Frost & Sullivan presents a Company of the Year award to the organization that demonstrates excellence in terms of growth strategy and implementation in its field. The award recognizes a high degree of innovation with products and technologies, and the resulting leadership in terms of customer value and market penetration.
Frost & Sullivan Best Practices awards recognize companies in various regional and global markets for demonstrating outstanding achievement and superior performance in leadership, technological innovation, customer service, and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analyses, and extensive secondary research to identify best practices in the industry.
About Frost & SullivanFor six decades, Frost & Sullivan has been world-renowned for its role in helping investors, corporate leaders, and governments navigate economic changes and identify disruptive technologies, Mega Trends, new business models, and companies to action, resulting in a continuous flow of growth opportunities to drive future success. Contact us: Start the discussion.
Contact:Tarini SinghP: +91-9953764546E:[email protected]
About SJMC
Subang Jaya Medical Centre (SJMC)
SJMC has an impeccable reputation as one of Malaysia’s most trusted private medical centres best known for its clinical outcomes. The hospital is an award-winning 443-bed multi-disciplinary tertiary hospital of CAH Medical Centres (previously known as Ramsay Sime Darby Health Care Group), providing comprehensive and complex care in all specialties.
It is one of the few internationally accredited Joint Commission International (JCI) hospitals in Malaysia and Malaysian Society for Quality in Health (MSQH) accredited. SJMC’s laboratory is also an internationally recognized MS ISO 15189 accredited since 2009. In 2023, SJMC Oncology (Cancer) Services is certified by Australian Council of Healthcare Standards (ACHS) International as a Centre of Excellence, making it the first in Asia-Pacific.
SJMC is recognized as a finalist for the Flagship Medical Tourism Hospital Programme 2023 – 2025 by Malaysia Healthcare Travel Council (MHTC) to establish Malaysia as a globally renowned icon for healthcare travel, delivering exceptional end-to-end patient experiences anchored on medical excellence, service excellence, and international branding. It receives both local patients across Malaysia and international patients across the Asia Pacific with over 47,000 admissions and almost half a million outpatient visits annually.
For more information, contact:Celia TanP: +60 17 930 8200E: [email protected]
Nur Yee Jie MinP: +012 355 1885E: [email protected]
Photo – https://mma.prnewswire.com/media/2415752/SJMC_Award.jpg
View original content:https://www.prnewswire.co.uk/news-releases/subang-jaya-medical-centre-applauded-by-frost–sullivan-as-the-best-hospital-company-of-the-year-in-malaysia-for-the-fourth-consecutive-year-302148854.html
Artificial Intelligence
More than $9 Million Awarded to High School Scientists and Engineers at the Regeneron International Science and Engineering Fair 2024
Grace Sun, 16, receives $75,000 Top Award for a new kind of organic electrochemical transistor at the world’s largest pre-college science, technology, engineering and math (STEM) competition.
TARRYTOWN, N.Y. and WASHINGTON, May 17, 2024 /PRNewswire/ — Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Society for Science (the Society) announced that Grace Sun, 16, of Lexington, Kentucky, won the $75,000 top award, the George D. Yancopoulos Innovator Award, named in honor of the pioneering drug researcher and Regeneron co-Founder, Board co-Chair, President and Chief Scientific Officer, in the 2024 Regeneron International Science and Engineering Fair (Regeneron ISEF), the world’s largest pre-college science and engineering competition. Other top prizes went to projects in second-order cone programming, microplastics filtration and multi-sensory therapy for dementia.
The top winners were honored during two award ceremonies: the Special Awards on May 16 and the Grand Awards Ceremony on the morning of May 17. In total, over $9 million USD was awarded to the finalists based on their projects’ creativity, innovation and depth of scientific inquiry. The competition featured nearly 2,000 young scientists representing 49 U.S. states and nearly 70 countries, regions and territories across the world.
Grace Sun, 16, of Lexington, Kentucky, won first place and received the $75,000 George D. Yancopoulos Innovator Award for her research on building a better organic electrochemical transistor that she hopes will be used to develop new electronic devices that could help detect and treat serious illnesses like diabetes, epilepsy and organ failure. To overcome the problems that have previously prevented such devices from working effectively inside the body, Grace developed a new way of chemically treating their organic components, which greatly improved their laboratory performance.
Michelle Wei, 17, of San Jose, California, received one of two Regeneron Young Scientist Awards of $50,000 for her research to improve the speed and efficiency of a type of software that is useful in many fields such as machine learning, transportation and financial systems. Michelle’s new approach involved determining a quick approximate solution to the second-order cone programming problem, then splitting the initial cone into smaller cones, which enabled her new algorithm to greatly outperform previous approaches.
Krish Pai, 17, of Del Mar, California, received the second Regeneron Young Scientist Award of $50,000 for his machine-learning research to identify microbial genetic sequences that can be modified to biodegrade plastic. His new software, called Microby, scans databases of microorganisms and determines which ones can be changed genetically to biodegrade plastics. In tests, he identified two microorganisms that can be genetically modified to degrade plastic at a cost he believes would be ten times less than traditional recycling.
“Congratulations to the Regeneron International Science and Engineering Fair 2024 winners,” said Maya Ajmera, President and CEO, Society for Science and Executive Publisher, Science News. “I’m truly inspired by the ingenuity and determination shown by these remarkable students. Coming from around the world with diverse backgrounds and academic disciplines, these students have shown that it is possible to come together in unity to tackle some of the toughest challenges facing our world today, and I could not be prouder.”
Regeneron ISEF provides a global stage for the world’s best and brightest young scientists and engineers. Through this competition, Regeneron and the Society are fostering the next generation of STEM leaders who are pioneering solutions to improve our world. Since 2020, Regeneron has provided STEM experiences to approximately 2.4 million students, on track to meet its goal of 2.5 million by 2025.
“The talent, intelligence and potential of this year’s Regeneron ISEF finalists is truly inspiring, and I congratulate each on their remarkable achievements,” said George D. Yancopoulos, M.D., Ph.D., co-Founder, Board co-Chair, President and Chief Scientific Officer of Regeneron. “Science competitions like ISEF were pivotal in shaping my own career and fueling my passion to fight back against disease. I look forward to seeing these students continue to push the boundaries of science and technology to create positive and sustainable change for all humanity.”
Other top honors from the competition include:
Justin Huang and Victoria Ou, both 17, of Woodlands, Texas, received the Gordon E. Moore Award for Positive Outcomes for Future Generations of $50,000 for their new prototype filtration system that uses ultrasonic waves to remove microscopic plastic particles from water. In lab tests, the acoustic force from the high-frequency sound waves removed between 84% and 94% of the suspended microplastic particles in a single pass. The students are now working to scale up and fine-tune their experimental system.
Ingrid Wai Hin Chan, 17, of Hong Kong, China received the Craig R. Barrett Award for Innovation of $10,000 for her research on using a multi-sensory therapy for dementia patients. Her mixed therapy app would allow patients to practice physical and cognitive skills through a personalized, immersive environment using virtual reality headsets. Ingrid conducted an eight-week study with six people living with dementia and found that the cognitive function of patients who used her prototype improved in several areas. She believes her app could serve as a viable option for dementia patients with limited access to in-person professional therapy.
Tanishka Balaji Aglave, 15, of Valrico, Florida, received the H. Robert Horvitz Prize for Fundamental Research of $10,000 for her investigation into a natural alternative treatment against citrus greening, a disease that threatens citrus farming in many parts of the world and is currently only treated with antibiotics. Tanishka injected the trunks of infected trees with an extract from the curry leaf tree, and found through tests that this potential method could effectively and sustainably manage citrus greening disease.
Maddux Alexander Springer, 18, of Honolulu, Hawaii, received the Peggy Scripps Award for Science Communication of $10,000 for his research into fibropapillomatosis (FP), a disease that is the primary cause of death in green sea turtles. Some turtles he studied in Kaneohe Bay, Hawaii, were stricken with a disease that causes internal and external tumors that inhibit their everyday lives. After analyzing the turtles’ diet of green algae, Maddux concluded that this disease, wastewater, invasive algae and the amino acid arginine all pose a grave risk to these endangered sea creatures.
Ria Kamat, 17, of Hackensack, New Jersey; Anna Oliva, 17, of Houston, TX; and Shuhan Luo, 18, of Worcester, MA, received the Dudley R. Herschbach SIYSS Award, which provides finalists an all-expense paid trip to attend the Stockholm International Youth Science Seminar during Nobel Week in Stockholm, Sweden.
Jack Shannon, 18, of Clane, Kildare, Ireland, and Nikhil Vemuri, 17, of Cary, North Carolina, received the EU Contest for Young Scientists Award. Their projects will represent Regeneron ISEF at the EU Contest for Young Scientists to be held this September in Katowice, Poland.
For more information about the top winners and access to visual assets visit: https://www.societyforscience.org/isef-2024-media-kit.
The full list of Special Award ISEF 2024 Finalists can be found at https://www.societyforscience.org/press-release/regeneron-isef-2024-special-awards-winners.
In addition to the Top Award winners, more than 450 finalists received awards and prizes for their innovative research, including “First Award” winners, who each received a $5,000 prize.
The following lists the First Award winners for each of the 22 categories, from which the Top Awards were chosen:
Animal Sciences, sponsored by Society for ScienceMaddux Alexander Springer, Honolulu, Hawaii
Behavioral and Social Sciences, sponsored by Society for ScienceAndrew Y. Liang, San Jose, California
Biochemistry, sponsored by RegeneronAmy Hong Xiao, Garden City, New York
Biomedical and Health Sciences, sponsored by RegeneronRia Kamat, Hackensack, New Jersey; Kevin Xuan Lei, Shanghai, China
Biomedical Engineering, sponsored by Alfred E. Mann CharitiesAyush Garg, Dublin, California; Divij Motwani, Palo Alto, California; Akash Ashish Pai, Portland, Oregon
Cellular and Molecular Biology, sponsored by RegeneronLara and Maya Sarah Hammoud, Beverly Hills, Michigan
Chemistry, sponsored by Society for ScienceAkilan Sankaran, Albuquerque, New Mexico; Arjun Suresh Malpani and Siddharth Daniel D’costa, Portland, Oregon
Computational Biology and Bioinformatics, sponsored by RegeneronKun-Hyung Roh, Bronx, New York
Earth and Environmental Sciences, sponsored by Google.orgNikhil Vemuri, Durham, North Carolina; Justin Yizhou Huang and Victoria Ou, The Woodlands, Texas
Embedded Systems, sponsored by HPChloe Rae and Sophie Rose Filion, Welland, Ontario, Canada
Energy: Sustainable Materials and Design, sponsored by Siemens EnergyAlia Wahban, Hamilton, Ontario, Canada
Engineering Technology: Statics and Dynamics, sponsored by Howmet Aerospace FoundationChiyo Nakatsuji, Bunkyoku, Tokyo, Japan; Kevin Shen, Olympia, Washington
Environmental Engineering, sponsored by JacobsKrish Pai, San Diego, California; Jack Shannon, Clane, Kildare, Ireland
Materials Science, sponsored by Howmet Aerospace FoundationGrace Sun, Lexington, Kentucky
Mathematics, sponsored by Akamai FoundationAnna Oliva, Houston, Texas
Microbiology, sponsored by Schattner FoundationMatthew Chang, Irvine, California
Physics and Astronomy, sponsored by Richard F. Caris Charitable Trust IIHarini Thiagarajan and Vishal Ranganath Yalla, Bothell, Washington; Shuhan Luo, Worcester, Massachusetts
Plant Sciences, sponsored by Society for SciencePauline Estrada, Fresno, California; Tanishka Balaji Aglave, Dover, Florida
Robotics and Intelligent Machines, sponsored by RegeneronMichal Lajciak, Dubnica nad Vahom, Trenciansky kraj, Slovakia; Anthony Efthimiadis, Oakville, Ontario, Canada
Systems Software, sponsored by MicrosoftMichelle Wei, San Jose, California
Technology Enhances the Arts, sponsored by Society for ScienceAnant Khandelwal, Sritan Motati and Siddhant Sood, Alexandria, Virginia
Translational Medical Science, sponsored by RegeneronZheng-Chi Lee, West Lafayette, Indiana; Ingrid Wai Hin Chan, Hong Kong, China
The full list of all award-winning ISEF 2024 finalists is available here: https://www.societyforscience.org/press-release/regeneron-isef-2024-full-awards.
View all the finalists’ research here: https://projectboard.world/isef.
About the Regeneron International Science and Engineering FairThe Regeneron International Science and Engineering Fair (Regeneron ISEF), a program of Society for Science for over 70 years, is the world’s largest global science competition for high school students. Through a global network of local, regional and national science fairs, millions of students are encouraged to explore their passion for scientific inquiry. Each spring, a group of these students is selected as finalists and offered the opportunity to compete for approximately U.S. $9 million in awards and scholarships.
In 2019, Regeneron became the title sponsor of ISEF to help reward and celebrate the best and brightest young minds globally and encourage them to pursue careers in STEM to positively impact the world. Regeneron ISEF is supported by a community of additional sponsors, including Akamai Foundation, Alfred E. Mann Charities, Aramco, Caltech, Google.org, Gordon and Betty Moore Foundation, Howmet Aerospace Foundation, HP, , Jacobs, King Abdulaziz & his Companions Foundation for Giftedness and Creativity, Microsoft, National Geographic Society, Richard F. Caris Charitable Trust II, Rise, an initiative of Schmidt Futures and the Rhodes Trust, Schattner Foundation, Siemens Energy, Annenburg Foundation, Ballmer Group, Broadcom Foundation, Cesco Linguistic Services, Conrad N. Hilton Foundation, Edison International, Insaco, Oracle Academy, The Eli and Edythe Broad Foundation, The Ralph M. Parsons Foundation and US Army ROTC. Many are entrepreneurs across a wide range of industries. Learn more at https://www.societyforscience.org/isef/.
About Society for ScienceSociety for Science is a champion for science, dedicated to promoting the understanding and appreciation of science and the vital role it plays in human advancement. Established in 1921, Society for Science is best known for its award-winning journalism through Science News and Science News Explores, its world-class science research competitions for students, including the Regeneron Science Talent Search, the Regeneron International Science and Engineering Fair and the Thermo Fisher Scientific Junior Innovators Challenge, and its outreach and equity programming that seeks to ensure that all students have an opportunity to pursue a career in STEM. A 501(c)(3) membership organization, Society for Science is committed to inform, educate and inspire. Learn more at www.societyforscience.org and follow us on Facebook, Twitter, Instagram and Snapchat (Society4Science).
About RegeneronRegeneron (NASDAQ: REGN) is a leading biotechnology company that invents, develops and commercializes life-transforming medicines for people with serious diseases. Founded and led by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to numerous approved treatments and product candidates in development, most of which were homegrown in our laboratories. Our medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases and rare diseases.
Regeneron believes that operating as a good corporate citizen is crucial to delivering on our mission. We approach corporate responsibility with three goals in mind: to improve the lives of people with serious diseases, to foster a culture of integrity and excellence and to build sustainable communities. Regeneron is proud to be included on the Dow Jones Sustainability World Index and the Civic 50 list of the most “community-minded” companies in the U.S. Throughout the year, Regeneron empowers and supports employees to give back through our volunteering, pro bono and matching gift programs. Our most significant philanthropic commitments are in the area of early science education, including the Regeneron Science Talent Search and the Regeneron International Science and Engineering Fair (ISEF).
For more information, please visit www.Regeneron.com or follow Regeneron on LinkedIn, Instagram, Facebook or X.
More information about the top winners and access to visual assets visit: https://www.societyforscience.org/isef-2024-media-kit.
Media ContactsJoseph Brown, [email protected]
Gayle Kansagor, Society for [email protected]
Photo – https://mma.prnewswire.com/media/2416174/Regeneron_ISEF_2024_Winners_Photo.jpg
Logo – https://mma.prnewswire.com/media/2416197/Society_for_Science_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/more-than-9-million-awarded-to-high-school-scientists-and-engineers-at-the-regeneron-international-science-and-engineering-fair-2024-302149316.html
-
Uncategorized7 days agoCrossover Markets Becomes First Crypto ECN to Integrate with Talos
-
Artificial Intelligence7 days agoMSI Highlights Optimized AI Platforms to Accelerate Compute-Intensive Applications at ISC 2024
-
Uncategorized7 days ago
Precisely Showcases Critical Role of Trusted Data in AI at the Gartner® Data & Analytics Summit in London
-
Artificial Intelligence6 days agoAdvanced HPC Server Platforms by MiTAC and TYAN Spotlighted at ISC High Performance 2024
-
Uncategorized5 days ago
Artificial intelligence tool detects sex-related differences in brain structure
-
Artificial Intelligence3 days agoJapan Data Center Market Investment to Reach $14.48 Billion by 2028 – Watch Out Exclusive Insight on Japan & Hong Kong Data Center Market – Arizton
-
Artificial Intelligence3 days agoStrava Unveils New Chapter of Accelerated Product Development at Brand’s Flagship Event
-
Artificial Intelligence7 days ago
Supermicro’s Rack Scale Liquid-Cooled Solutions with the Industry’s Latest Accelerators Target AI and HPC Convergence
